BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc

Reuters01-09

Jan 9 (Reuters) - CG Oncology Inc CGON.O:

CG ONCOLOGY PROVIDES UPDATED TIMELINE FOR PIVOT-006 PHASE 3 TOPLINE DATA IN INTERMEDIATE-RISK NMIBC
CG ONCOLOGY INC - EXPECTS PHASE 3 PIVOT-006 DATA IN 1H 2026

Source text: ID:nGNX9Y2PmR

Further company coverage: CGON.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602371602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602371602","market":"nz","top_or_hot":-1,"title":"BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc</title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CGON\">CG Oncology</a> Inc <span>CGON.O</span>:</p><ul><li><p>CG ONCOLOGY PROVIDES UPDATED TIMELINE FOR PIVOT-006 PHASE 3 TOPLINE DATA IN INTERMEDIATE-RISK NMIBC</p></li><li><p>CG ONCOLOGY INC - EXPECTS PHASE 3 PIVOT-006 DATA IN 1H 2026</p></li></ul><p>Source text: <span>ID:nGNX9Y2PmR</span></p><p>Further company coverage: <span>CGON.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 22:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc</title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CGON\">CG Oncology</a> Inc <span>CGON.O</span>:</p><ul><li><p>CG ONCOLOGY PROVIDES UPDATED TIMELINE FOR PIVOT-006 PHASE 3 TOPLINE DATA IN INTERMEDIATE-RISK NMIBC</p></li><li><p>CG ONCOLOGY INC - EXPECTS PHASE 3 PIVOT-006 DATA IN 1H 2026</p></li></ul><p>Source text: <span>ID:nGNX9Y2PmR</span></p><p>Further company coverage: <span>CGON.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9MH8SQ:1","article_id":"2602371602","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602371602","pubTimestamp":1767967608,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk NmibcJan 9 (Reuters) - CG Oncology Inc CGON.O:CG ONCOLOGY PROVIDES UPDATED TIMELINE FOR PIVOT-006 PH","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CGON":"CG Oncology Inc."},"translate_title":"简介-Cg Oncology提供中风险Nmibc中PIVOT-006 III期顶线数据的更新时间表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGON":0.9},"content_text":"BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk NmibcJan 9 (Reuters) - CG Oncology Inc CGON.O:CG ONCOLOGY PROVIDES UPDATED TIMELINE FOR PIVOT-006 PHASE 3 TOPLINE DATA IN INTERMEDIATE-RISK NMIBCCG ONCOLOGY INC - EXPECTS PHASE 3 PIVOT-006 DATA IN 1H 2026Source text: ID:nGNX9Y2PmRFurther company coverage: CGON.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602371602","isCrawlerRequest":true}